-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Clinical trials have shown that oral antidiabetic drugs (OADs) can significantly reduce glycated hemoglobin (HbA1c) levels
Oral antidiabetic drugs (OADs) can significantly reduce glycated hemoglobin (HbA1c) levels
RESULTS: Among 57,910 patients, 43,338 used OAD at least once, and a total of 76,990 had HbA1c values related to OAD dose
Table 1 Changes in HbA1c values after using metformin (HbA1c is expressed in mmol/mol)
Table 1 Changes in HbA1c values after using metformin (HbA1c is expressed in mmol/mol)Table 2 Changes in HbA1c values with glipizide (HbA1c expressed in mmol/mol)
Table 2 Changes in HbA1c values with glipizide (HbA1c expressed in mmol/mol)Table 3 Changes in HbA1c values with gliclazide (HbA1c expressed in mmol/mol)
Table 3 Changes in HbA1c values with gliclazide (HbA1c expressed in mmol/mol)Figure 1 Changes of HbA1c (HbA1c expressed in mmol/mol) under different OAD doses
Figure 1 Changes of HbA1c (HbA1c expressed in mmol/mol) under different OAD doses
Real-world data from Asian T2DM patients in this study showed that the magnitude of OAD initiation and dose changes was slightly lower than the results of clinical trials
Fang HSA, Gao Q, Tan WY, et al.
leave a message here
